Real Tech Fund works on new antibody drug development
Invested in "Epsilon Molecular Engineering Co., Ltd."

Euglena Investment Co., Ltd.

　Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) is a new investment destination for the R & D-specialized venture capital fund "Real Tech Fund", Epsilon Molecular Engineering Co., Ltd. (hereinafter, EME). We would like to inform you that we have invested in.

　Based on evolutionary molecular engineering * 1, EME is engaged in R & D contracts and joint research on the development of pharmaceuticals and diagnostic agents using biofunctional molecular design * 2, and new antibodies * 3 that it has acquired independently. A company that develops antibody drugs.
　The Real Tech Fund will underwrite the shares issued by EME through a third-party allotment, and the 2017 “Research” by the National Research and Development Corporation New Energy and Industrial Technology Development Organization (NEDO), which was adopted by EME. Development-type venture support business / Commercialization support for R & D-type ventures in the seed period ”As a certified VC of the subsidy business, we will support the company's research and development, sales and marketing activities.
　The details are as follows.

* 1 Evolutionary molecular engineering: A discipline that designs molecules with new functions by applying the evolutionary process of living organisms.
* 2 Biofunctional molecule design: Creating biomolecules with new functionality.
* 3 Antibodies: The core substances of the immune system that specifically recognize and attack foreign substances such as viruses, bacteria, and cancer cells that have invaded the body.

About investment in Epsilon Molecular Engineering Co., Ltd.

■ About Epsilon Molecular Engineering Co., Ltd. Outline and support contents
　Date of establishment: August 19, 2016
　location　: 255 Shimookubo, Sakura-ku, Saitama-shi, Saitama Saitama University Innovation Center Room 201
　Representative　: Representative Director Naoto Nemoto
　Capital　: 21.13 million yen (excluding capital reserve)
　Business: Research and development of biotechnology and bioinformatics centered on evolutionary molecular engineering, pharmaceuticals and medical examinations using biofunctional molecular design
　　　　　　R & D contracts and joint research to develop drug withdrawals, etc.
　HP　　: Http://www.epsilon-mol.co.jp
　 Support content: Promotion of cooperation with fund-funded companies, support for research and development, sales and marketing activities
　Investment period: August 2017

■ About Realtech Fund (HP: http://www.realtech.fund/)
　Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 30 participating companies and a fund size of 9.4 billion yen (as of October 2017), it is one of the largest real tech-specialized funds in Japan. We are investing in and nurturing real tech ventures with the following operating companies that are investors.

that's all　　　　　　　　

 -Contact for inquiries from the press-
Euglena Co., Ltd. Corporate Communication Division